Helmy Eltoukhy

Co-CEO Helmy Eltoukhy sells 100,000 shares ($12.6M) across 7 transactions at GH on 2026-06-05

Helmy Eltoukhy, Co-Chief Executive Officer of Guardant Health, executed 7 separate sales totaling 100,000 shares for $12,629,968.55 on a single trading day, reducing his holdings by 100,000 shares from 2,112,919 to 2,012,919 shares. The blended average price of $126.30 across these transactions sits near the current price of $124.89, and notably, the stock is trading at -7.0% from its 52-week high of $134.28, having recently gained +30.5% over the past 30 days and +38.0% over 90 days. At the same ticker, his prior two sales on 2025-12-15 showed mixed timing outcomes (30d +4.6% and +4.4% but 90d -17.6% and -17.8%), while his two sales on 2025-09-09 demonstrated stronger near-term continuation (+30.5% and +38.0% at 30 and 90 days). The company itself remains unprofitable with net income of $-112,075,000.00 on revenue of $301,665,000.00 in the latest quarter, though it is growing revenue at +32.9% annually.

Co-CEO Helmy sold 90,565 shares at blended $103.82, netting $9.4M; stock now $97.47, down 12.4% from 52-week high.

Eltoukhy Helmy executed 2 separate sales totaling 90,565 shares for $9,402,220.02 at an average price of $103.82, reducing his holdings from 2,137,708 to 2,047,143 shares (a 4.2% reduction). The stock has since declined to $97.47, trading 12.4% below its 52-week high of $111.25. Notably, Helmy's prior 2 sales at GH both showed positive 90-day returns (the stock rose 75.2% and 73.8% after those trades), meaning neither was well-timed; his cross-ticker track record shows a 0.00% well-timed rate across 2 prior sells. The company remains unprofitable (net income −$92.7M in latest full year) despite strong 31.0% annual revenue growth, adding structural uncertainty to the valuation context in which this sale occurred.

Co-CEO Eltoukhy sells 300,000 GH shares for $17.8M at $59.45 avg, retains 2.12M shares post-sale.

Helmy Eltoukhy, Co-Chief Executive Officer, executed 2 separate sales totaling 300,000 shares for $17,835,995.20 on 2025-09-09 at a blended average price of $59.45, reducing his stake by 12.4% to 2.12M shares. The sale occurred 3.2% above the current price of $56.80, though 15.8% below the 52-week high of $67.42. Guardant Health remains unprofitable on a full-year basis with $-99.9M net income, though the company posted +31.0% annual revenue growth to $232.1M in its latest quarter. The timing of a significant insider reduction in a high-growth but unprofitable biotech company warrants investor attention regarding management's medium-term outlook on near-term cash burn or profitability trajectory.